Answers are grounded in this paper and cite their sources.
Liraglutide resulted in dose-independent, reversible increases in amylase/lipase activity, unrelated to baseline characteristics, not predicting AP onset. Gallstones possibly contributed to 50% of AP cases. Data provide no basis for amylase/lipase level monitoring in liraglutide treatment except in suspected AP.
No takes yet. Share an insight, caveat, or question.
Steinberg et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: